LEXINGTON, Mass., May 3, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its first quarter 2018 financial results before the market opens on Monday, May 07,

LEXINGTON, Mass., May 1, 2018 / PRNewswire / -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Andy Hurwitz, Vice President, Head of

LEXINGTON, Mass., April 11 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that three abstracts were accepted for presentation at the AACR 2018 Annual Meeting in Chicago from April

LEXINGTON, Mass., March 29, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's leadership will present and host one-on-one meetings at two healthcare

LEXINGTON, Mass. , March 15, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for fourth quarter and full year 2017.

LEXINGTON, Mass., March 7, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and full year 2017 financial results before the market opens on Thursday, March 15, 2018.

LEXINGTON, Mass., Jan. 22, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).

- Combination trial accrual completed in first cohort of patients - Commercial grade AGEN1884 and AGEN2034 to be available by mid-year - Non-exclusive access to partners for clinical and commercial supplies LEXINGTON, Mass., Jan. 22, 2018 / PRNewswire / -- Agenus Inc.

LEXINGTON, Mass., Jan. 8, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).

LEXINGTON, Mass., Jan. 4, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle, Head of Translational Medicine and Bioinformatics ,  will participate in a panel